Jubilant Pharmova Limited has informed the Exchange that Board of Directors at its meeting held on May 16, 2025, recommended Final Dividend of 5 per equity share.
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Smallcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors of Jubilant Pharmova Limited, at its meeting held on May 16, 2025, approved the audited financial results (standalone and consolidated) for Q4 and FY ended March 31, 2025, with the auditor issuing an unmodified opinion. The Board recommended a final dividend of Rs. 5 per equity share (500% on face value of Re. 1), totaling about Rs. 796 million, subject to shareholder approval. The record date has been fixed as July 25, 2025, and the dividend will be paid within 30 days of the AGM. For FY25, consolidated revenue from operations grew to Rs. 72,345 million from Rs. 67,029 million, while net profit jumped sharply to Rs. 8,363 million from Rs. 727 million, boosted by a Rs. 6,715 million gain from the sale of its stake in SOFIE Biosciences. EPS for the year stood at Rs. 52.99 versus Rs. 4.87 in the previous year.
The strong profit growth was largely supported by a one-time exceptional gain from the SOFIE stake sale, so underlying business performance should be looked at carefully. The Rs. 5 dividend is a modest payout, and the company used the SOFIE proceeds to reduce debt, which is a positive for balance sheet strength. The record date of July 25 makes existing shareholders eligible for the final dividend.